Postępy Dermatologii i Alergologii

Abstract

4/2022 vol. 39
Letter to the Editor

Sustained drug-related reaction with eosinophilia and systemic symptoms (DRESS) triggered by low molecular weight heparins in COVID-19: management and precision diagnosis

  1. Department of Medical and Surgical Sciences, Chair of Allergology and Clinical Immunology, University of Foggia, Foggia, Italy
  2. Department of Medical and Surgical Sciences, Chair of Respiratory Diseases, University of Foggia, Foggia, Italy
  3. Department of Emergency and Organ Transplantation, School and Chair of Allergology and Clinical Immunology, University of Bari – Aldo Moro, Bari, Italy
Adv Dermatol Allergol 2022; XXXIX (4): 816-818
Online publish date: 2021/10/01
View full text
Low molecular weight heparins (LMWHs), particularly enoxaparin, are administered routinely to Coronavirus disease 2019 (COVID-19) patients, in order to treat or prevent the associated, possibly serious coagulation disorders [1].

Both immunoglobulin E (IgE)-mediated and non IgE-mediated systemic reactions to LMWHs are considered rare [2–4]. Particularly, a single case of the drug-related reaction with eosinophilia and systemic symptoms (DRESS) has been documented in the literature [4].

Here we report on an elderly COVID-19 patient who developed DRESS upon prophylactic treatment with enoxaparin. Etiological diagnosis was corroborated by the lymphocyte proliferation test (LPT) [5] upon recovery. The management strategy adopted is outlined and commented.
Share
without publication fees